{
  "question": "What are the small molecules that will form some kind of protein-ligand interactions with the chemical represented by ChEMBL ID: CHEMBL4803817?\nOnce you feel you are ready for the final answer, directly return the answer with the format <<<answer content>>> at the end of your response, e.g. <<<C>>>, <<<9.8>>>.",
  "response_list": [
    "### No Small Molecules Documented to Directly Bind Angiopoietin-1\n\nThe chemical entity identified by ChEMBL ID CHEMBL4803817 is Angiopoietin-1 (Ang1), a crucial protein involved in the development and maturation of blood vessels. While this protein is a significant target in medical research, particularly for diseases involving blood vessel growth like cancer, there is no widespread documentation of small molecules that form direct protein-ligand interactions with Angiopoietin-1 itself.\n\nThe primary mechanism through which Angiopoietin-1's activity is modulated is by targeting its interaction with its principal receptor, the Tie2 receptor tyrosine kinase. Research and therapeutic development have predominantly focused on two main strategies:\n\n*   **Inhibiting the Tie2 Receptor:** Numerous small molecules have been developed as inhibitors of the Tie2 kinase. These molecules act on the receptor to block the signaling cascade that Angiopoietin-1 would normally initiate. Examples of such small molecules that inhibit Tie2 include rebastinib, regorafenib, and cabozantinib, though these are often multi-kinase inhibitors. Another study identified developmental compounds, referred to as \"compound 1\" and \"compound 7\", as potent small-molecule inhibitors of Tie2.\n*   **Blocking the Ang1-Tie2 Interaction with Biologics:** Larger therapeutic molecules, known as biologics, have been designed to physically block Angiopoietin-1 from binding to Tie2. These are not small molecules. One such example is **mL4-3**, which has been described as a selective inhibitor of Angiopoietin-1. However, mL4-3 is a \"peptibody,\" a fusion of a peptide and an antibody fragment, classifying it as a large-molecule biologic, not a small molecule. Another agent, Trebananib, is also a peptibody that neutralizes both Angiopoietin-1 and the related Angiopoietin-2.\n\nIn addition to its main receptor Tie2, Angiopoietin-1 can also interact with other proteins, notably integrins on the cell surface. These interactions can be blocked by molecules like RGD-based peptides; however, these are peptides and not considered small molecules in the conventional sense.\n\nIn summary, despite extensive research into the Angiopoietin-1 pathway, the scientific literature does not point to specific small molecules that have been designed or discovered to bind directly to Angiopoietin-1. The overwhelming focus has been on inhibiting its receptor, Tie2, with small molecules or blocking the protein's binding site with larger biologics.\n\n<<<Based on the available information, there are no well-documented small molecules that form a direct protein-ligand interaction with Angiopoietin-1 (CHEMBL4803817). Therapeutic and research strategies primarily target its receptor, Tie2, or use large-molecule biologics to block its function.>>>"
  ],
  "user_prompt_list": [
    "What are the small molecules that will form some kind of protein-ligand interactions with the chemical represented by ChEMBL ID: CHEMBL4803817?\nOnce you feel you are ready for the final answer, directly return the answer with the format <<<answer content>>> at the end of your response, e.g. <<<C>>>, <<<9.8>>>."
  ],
  "system_message": ""
}